{"success":true,"data":{"pressRelease":{"id":"162175","rtpr_id":"nGNX10dkMV-20261006","ticker":"AVXL","exchange":"NASDAQ","all_tickers":["AVXL"],"title":"AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS Law","author":"Globe Newswire","published_at":"2026-10-06T14:32:06.095Z","article_body":"LOS ANGELES, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=e8Z0zcGRFlnFEMLL-nnHxsanvjQiFvVH3_OXuZKh5Yw3AaGoI2aRqRfyad4zPj8dikYETzjI43PMQl7Wpuaj4lxUETZ13PsfqJZhum2TXtX4K1ew3xsTV5yeyJqBp4hB)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or\n“the Company”) (NASDAQ: AVXL\n(https://www.globenewswire.com/Tracker?data=AxZiMtwwL6CiPEZgordHk-rOqwozKTBSHTIJ4uqygvKqTThevZK_aQM-16UuSka1tyQ9NHyiyzEOdrWzlIxD2EICJ5I3PkEb5f487u6z43c=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of AVXL during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: November 26, 2025 to August 28, 2026\n\nDEADLINE: November 30, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=8l9cTMLW8iqjvRo6ivL1b49tp0w-Ahh6mWNWIz0ghzHzlo-kx6-HDdrFki7nxpnKwyEFHM6XKNR4h4qwNiAIEcju0TMcPQ_pt9gzMjfgPFOLHv9LyUSXFcsVxcp251q90VXnocQCw8p8I2oZu4_6LQ==).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Anavex failed to maintain adequate\ninternal controls. The Company downplayed the potential regulatory headwinds\nit faced due to former CEO Christopher Missling’s misconduct. Based on these\nfacts, the Company’s public statements were false and materially misleading\nthroughout the class period. When the market learned the truth about Anavex,\ninvestors suffered damages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=1_MIos98AOOkwXNxY2yKuXmPuwtVNXJ8j254NvVeofyp7LdxZwzKvtuPS_kid3Dg0rO3g8ni7Y0fXMMSlvY7UFmcdMAGfu1WcpE8BtL9e3m6MgTOpC3EKtSJrucs4TbnTyvMknWwLl3NhA1fMhc7gg==)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\n Schall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX10dkMV-20261006","title":"AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit with SBS Law","author":"Globe Newswire","ticker":"AVXL","created":"2026-10-06T14:32:06.095Z","tickers":["AVXL"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP\n(https://www.globenewswire.com/Tracker?data=e8Z0zcGRFlnFEMLL-nnHxsanvjQiFvVH3_OXuZKh5Yw3AaGoI2aRqRfyad4zPj8dikYETzjI43PMQl7Wpuaj4lxUETZ13PsfqJZhum2TXtX4K1ew3xsTV5yeyJqBp4hB)\n(“SBS”), a national shareholder rights litigation firm, reminds investors\nof a class action lawsuit against Anavex Life Sciences Corp. (“Anavex” or\n“the Company”) (NASDAQ: AVXL\n(https://www.globenewswire.com/Tracker?data=AxZiMtwwL6CiPEZgordHk-rOqwozKTBSHTIJ4uqygvKqTThevZK_aQM-16UuSka1tyQ9NHyiyzEOdrWzlIxD2EICJ5I3PkEb5f487u6z43c=))\nfor violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934\nand Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange\nCommission.\n\nShareholders who purchased shares of AVXL during the class period listed are\nencouraged to contact the firm regarding possible lead plaintiff appointments.\nAppointment as lead plaintiff is not required to partake in any recovery.\n\nCLASS PERIOD: November 26, 2025 to August 28, 2026\n\nDEADLINE: November 30, 2026\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://www.globenewswire.com/Tracker?data=8l9cTMLW8iqjvRo6ivL1b49tp0w-Ahh6mWNWIz0ghzHzlo-kx6-HDdrFki7nxpnKwyEFHM6XKNR4h4qwNiAIEcju0TMcPQ_pt9gzMjfgPFOLHv9LyUSXFcsVxcp251q90VXnocQCw8p8I2oZu4_6LQ==).\n\nCASE DETAILS: According to the Complaint, the Company made false and\nmisleading statements to the market. Anavex failed to maintain adequate\ninternal controls. The Company downplayed the potential regulatory headwinds\nit faced due to former CEO Christopher Missling’s misconduct. Based on these\nfacts, the Company’s public statements were false and materially misleading\nthroughout the class period. When the market learned the truth about Anavex,\ninvestors suffered damages.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com, or by email\nat david@schallfirm.com.\n\nThe class, in this case, has not yet been certified, and until certification\noccurs, you are not represented by an attorney. If you choose to take no\naction, you can remain an absent class member.\n\nJoin the case\n(https://www.globenewswire.com/Tracker?data=1_MIos98AOOkwXNxY2yKuXmPuwtVNXJ8j254NvVeofyp7LdxZwzKvtuPS_kid3Dg0rO3g8ni7Y0fXMMSlvY7UFmcdMAGfu1WcpE8BtL9e3m6MgTOpC3EKtSJrucs4TbnTyvMknWwLl3NhA1fMhc7gg==)\nto recover your losses\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the world\nand specializes in securities class action lawsuits and shareholder rights\nlitigation. Bringing together the extensive experience and diverse skillsets\nof founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is\ndedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.        \n\nCONTACT:\n\nSchall, Brown & Schwartz LLP\nBrian Schall, Esq.,\nAndrew Brown, Esq.,\nDavid Schwartz, Esq.,\nwww.schallfirm.com\nOffice: 310-301-3335\ninfo@schallfirm.com\n\nSOURCE:\n\n Schall, Brown & Schwartz LLP\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/0b1ae5f6-3843-4b48-9c73-0b3760ba856a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T14:32:06.158381761Z","server_sent_at_ms":1791297126158},"received_at":"2026-10-06T14:32:06.213Z","source_url":null},"analysis":{"id":"150668","press_release_id":"162175","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["alleged securities fraud including inadequate internal controls","alleged misconduct by former CEO Christopher Missling creating regulatory headwinds"],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP issued a solicitation reminding AVXL investors of a pending securities fraud class action, with a lead plaintiff deadline of November 30, 2026.\n\nThe complaint alleges false and misleading statements, inadequate internal controls, and downplayed regulatory headwinds tied to former CEO Christopher Missling's misconduct during a class period of November 26, 2025 to August 28, 2026.\n\nThis is law-firm marketing rather than an issuer disclosure; the class has not yet been certified and no settlement is announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress; note prior CEO misconduct allegations as background only."},"keyFigures":{"customDimensions":{"class_period":"November 26, 2025 to August 28, 2026","lead_plaintiff_deadline":"November 30, 2026"}},"namedEntities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Christopher Missling","role":"former CEO of Anavex Life Sciences Corp."}],"products":[],"companies":[{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"},{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"issuer/target of class action"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Schall, Brown & Schwartz LLP. Class not yet certified, no settlement announced; boilerplate lead-plaintiff-deadline reminder with contact CTAs."},"tickerRelevance":{"others":[],"primary":"AVXL"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP issued a solicitation reminding AVXL investors of a pending securities fraud class action, with a lead plaintiff deadline of November 30, 2026.\n\nThe complaint alleges false and misleading statements, inadequate internal controls, and downplayed regulatory headwinds tied to former CEO Christopher Missling's misconduct during a class period of November 26, 2025 to August 28, 2026.\n\nThis is law-firm marketing rather than an issuer disclosure; the class has not yet been certified and no settlement is announced.","key_figures":{"customDimensions":{"class_period":"November 26, 2025 to August 28, 2026","lead_plaintiff_deadline":"November 30, 2026"}},"named_entities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"Christopher Missling","role":"former CEO of Anavex Life Sciences Corp."}],"products":[],"companies":[{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"},{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"issuer/target of class action"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T14:32:11.061Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4828,"modelName":"glm-5.3-flashx"}}